Is UroGen Pharma Ltd. (URGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.9% / 30% | 24.7% / 30% | 2.1% / 30% | 9.85% / 5% | ✗ NOT HALAL |
| DJIM | 12.9% / 33% | 24.7% / 33% | 2.1% / 33% | 9.85% / 5% | ✗ NOT HALAL |
| MSCI | 43.2% / 33% | 82.8% / 33% | 7.1% / 33% | 9.85% / 5% | ✗ NOT HALAL |
| S&P | 12.9% / 33% | 24.7% / 33% | 2.1% / 33% | 9.85% / 5% | ✗ NOT HALAL |
| FTSE | 43.2% / 33% | 82.8% / 33% | 7.1% / 50% | 9.85% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 88.7% | |
| Operating Margin | -50.5% | |
| Net Margin | -139.8% | |
| Return on Assets (ROA) | -32.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$162M |
| Free Cash Flow | -$163M |
| Total Debt | $128M |
| Current Ratio | 4.0 |
| Total Assets | $200M |
Price & Trading
| Last Close | $17.90 |
| 50-Day MA | $19.87 |
| 200-Day MA | $19.48 |
| Avg Volume | 775K |
| Beta | 1.4 |
|
52-Week Range
$3.42
| |
About UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is UroGen Pharma Ltd. (URGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), UroGen Pharma Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is UroGen Pharma Ltd.'s debt ratio?
UroGen Pharma Ltd.'s debt ratio is 12.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 43.2%.
What are UroGen Pharma Ltd.'s key financial metrics?
UroGen Pharma Ltd. has a market capitalization of $836M, and revenue of $110M. The company maintains a gross margin of 88.7% and a net margin of -139.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.